282 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27452283	241	Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.	Jadavpur University
26871660	68	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.	San Raffaele Scientific Institute
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26263024	47	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.	Universit£
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24735644	19	Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.	University of Lille
23376997	53	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.	Universit£
23375794	220	Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.	Nanjing University of Chinese Medicine
23353736	41	Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).	Second Military Medical University
23287054	46	Sulphonamides: Deserving class as MMP inhibitors?	Indian Institute of Technology (Bhu)
23458498	24	Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.	Universit£
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
23134659	74	Design and synthesis of procollagen C-proteinase inhibitors.	Fibrogen
22891645	83	Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).	Glaxosmithkline
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University of Technology
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
22737278	44	Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.	TBA
22658537	76	Natural products as a gold mine for selective matrix metalloproteinases inhibitors.	East China University of Science and Technology
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
22342144	72	Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.	Panthera Biopharma
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
19635666	119	Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.	Incyte
19095454	63	Current perspective of TACE inhibitors: a review.	The M. S. University of Baroda
17981034	51	1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.	Johnson & Johnson Pharmaceutical Research and Development
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
17980583	46	Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).	Johnson & Johnson Pharmaceutical Research and Development
18086526	85	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.	Johnson & Johnson Pharmaceutical Research and Development
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University of Jerusalem
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research and Development
18029173	316	Synthesis and evaluation of novel heterocyclic MMP inhibitors.	North Dakota State University
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
15139754	17	Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase.	De Novo Pharmaceuticals
15214773	76	Fragment-based drug discovery.	Sunesis Pharmaceuticals
15139760	110	Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.	The Hebrew University of Jerusalem
12930146	170	Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.	Institut De Recherches Servier
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
12773041	119	Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11831904	172	New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.	Nippon Organon K.K.
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
10649971	180	Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.	Parke-Davis Pharmaceutical Research
10882358	62	Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.	F. Hoffmann-La Roche
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
9888835	42	Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.	Procter and Gamble Pharmaceuticals
9733482	31	Discovery of potent, achiral matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
2153207	31	Phosphoramidate peptide inhibitors of human skin fibroblast collagenase.	University of Kentucky
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
12824028	75	Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.	Pfizer
11327577	86	Heterocycle-based MMP inhibitors with P2' substituents.	Procter and Gamble Pharmaceuticals
11677139	92	The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.	Wyeth-Ayerst Research
11591510	57	alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.	Pfizer
11206468	24	Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
11206467	44	The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.	Wyeth-Ayerst Research
11514167	88	The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.	Wyeth-Ayerst Research
11378378	34	Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.	Celltech-Chiroscience
11133099	43	Synthesis and activity of selective MMP inhibitors with an aryl backbone.	Pharmacia
10340614	20	Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.	Dupont Pharmaceuticals
10450979	4	Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.	University of Cambridge
10397503	40	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.	Universit£
9873598	39	The synthesis and biological activity of a novel series of diazepine MMP inhibitors.	Wyeth-Ayerst Research
22386984	67	In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.	Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22153941	140	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.	Astrazeneca
22018790	9	Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.	Scripps Florida
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22082667	67	Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.	Microbiotix
22088955	33	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.	Universit£
21925881	60	Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.	Johnson & Johnson Pharmaceutical Research & Development
21548582	57	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.	University of Illinois At Chicago
21866961	28	Selective water-soluble gelatinase inhibitor prodrugs.	University of Notre Dame
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21514700	56	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.	Universit£
21536437	219	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.	Astrazeneca
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21493063	67	MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
21300546	129	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.	Astrazeneca
24900296	38	Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors	TBA
20965620	50	Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).	Protera
21078557	34	Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.	Yonsei University
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20180536	128	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.	Universit£
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
19767207	17	Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.	Central Pharmaceutical Research Institute
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
18835710	69	Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.	Schering-Plough Research Institute
	97	Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket	TBA
	1	Asymmetric synthesis of a conformationally constrained N-phosphonoalkyl dipeptide	TBA
	30	Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics	TBA
	30	Orally active inhibitors of stromelysin-1 (MMP-3)	TBA
	60	Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides	TBA
	49	Phosphinic acid inhibitors of matrix metalloproteinases	TBA
	44	Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistry	TBA
	15	Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the N-carboxyalkylamine and glutaramide carboxylate series	TBA
	12	Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the succinamide hydroxamate series	TBA
	36	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostere	TBA
	18	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'	TBA
	47	Hydroxamate inhibitors of human gelatinase B (92 kDa)	TBA
	39	Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modifications	TBA
	19	Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitors	TBA
	15	Synthesis of thiophenol derivatives as inhibitors of human collagenase	TBA
	11	Inhibitors of human collagenase: dipeptide mimetics with lactam and azalactam moieties at the P2′/P3′ position	TBA
	66	Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines	TBA
	5	Inhibition of metalloproteinase by futoenone derivatives	TBA
	40	Novel indolactam-based inhibitors of matrix metalloproteinases	TBA
	14	Aminophosphonic acid containing inhibitors of human collagenase: modification of the P1 residue	TBA
	2	Synthesis and biological evaluation of a library containing potentially 1600 amides / esters. A strategy for rapid compound generation and screening.	TBA
	60	Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivatives	TBA
	76	Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivatives	TBA
	26	Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acids	TBA
19457660	90	Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.	Incyte
19410464	71	Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.	Wyeth Research
19329309	49	Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.	Wyeth Research
19261472	16	Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.	University of California
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
18782669	90	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.	Université
18691892	52	Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat.	Merck Research Laboratories
17719700	39	Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.	Università
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
18083558	112	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.	Johnson & Johnson Pharmaceutical Research and Development
18068976	132	Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.	Incyte
18036818	157	Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.	Incyte
18029177	57	A novel series of highly selective inhibitors of MMP-3.	Pfizer
17591762	102	Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.	Pfizer
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17256836	84	Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.	Incyte
17188863	107	Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
17027261	153	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
16723229	108	Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.	Wyeth Research
16632358	68	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.	Johnson & Johnson Pharmaceutical Research and Development
16516469	39	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.	Novartis Institutes For Biomedical Research
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16426848	80	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.	Wyeth Research
16420030	38	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.	Chinese Academy of Sciences
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16289878	35	Conversion of potent MMP inhibitors into selective TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16220975	40	Receptor flexibility in de novo ligand design and docking.	De Novo Pharmaceuticals
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16084720	83	Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.	Wyeth Research
16005220	52	Identification of potent and selective MMP-13 inhibitors.	Wyeth Research
16002291	24	Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.	Pfizer
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15911259	49	Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.	Pfizer
15908214	95	Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.	Bristol-Myers Squibb Pharmaceutical Research Institute
15837315	13	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.	Università
15780611	74	Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.	Pfizer
15745814	75	Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.	Wyeth Research
15686921	55	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).	Pharmaceutical Research Institute
15566296	142	Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.	Wyeth Research
15357971	228	Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15341955	52	Synthesis and evaluation of novel oxazoline MMP inhibitors.	North Dakota State University
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer
15261259	48	Benzodiazepine inhibitors of the MMPs and TACE. Part 2.	Wyeth Research
15055993	30	Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.	Hokkaido Collaboration Center N-21
15006405	20	Synthesis and biological activity of selective azasugar-based TACE inhibitors.	Organon K.K.
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University of Athens
14684295	109	Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.	Chinese Academy of Sciences
14643313	132	Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.	Bristol-Myers Squibb Pharmaceutical Research Institute
14643312	39	Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.	Bristol-Myers Squibb Pharmaceutical Research Institute
12951101	79	Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.	Pfizer
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12873518	81	Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.	Wyeth Research
12873505	20	Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12873504	36	Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12824039	56	Novel inhibitors of procollagen C-proteinase. Part 2: glutamic acid hydroxamates.	Combichem
12798337	6	Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.	Indiana University School of Medicine
12781190	113	Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
12781187	15	Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Organon K.K.
12729664	14	Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.	Université
12723945	167	Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
12668018	138	Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.	Wyeth-Ayerst Research
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
12270165	80	Benzodiazepine inhibitors of the MMPs and TACE.	Wyeth Research
11992783	78	Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.	Pfizer
11934588	69	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.	Wyeth-Ayerst Research
11934587	19	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.	Wyeth-Ayerst Research
11844676	48	Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.	Organon K.K.
11831905	33	New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.	Organon K.K.
11814800	14	Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin.	Organon K.K.
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11738583	45	Potent P1' biphenylmethyl substituted aggrecanase inhibitors.	Bristol-Myers Squibb Pharma
11708926	84	Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Glaxosmithkline
11677124	67	Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.	Abbott Laboratories
11591509	46	alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.	Pfizer
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11585439	44	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.	Dupont Pharmaceuticals
11563922	147	Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.	UniversitäT Bielefeld
11551755	18	Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.	British Biotech Pharmaceuticals
11543676	45	Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.	Université
11543675	104	N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.	Université
11514157	48	N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.	Glaxosmithkline
11454461	111	The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.	Procter and Gamble Pharmaceuticals
11428927	117	A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.	The Royal Danish School of Pharmacy
11412980	48	Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.	Abbott Laboratories
11412979	67	Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.	Abbott Laboratories
11354379	37	Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.	Pfizer
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
11297453	173	Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.	Procter and Gamble Pharmaceuticals
11229774	40	Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).	Pfizer
11229773	73	Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.	Pfizer
11212095	65	General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.	Institut De Recherches Servier
11150165	228	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.	Procter and Gamble Pharmaceuticals
10937713	186	Solid-phase synthesis of an arylsulfone hydroxamate library.	Rhone-Poulenc Rorer
10882354	19	Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.	Pfizer
10794702	340	Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.	Università
10669564	189	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
10639284	119	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.	University of Florida
10579851	151	New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.	Astrazeneca
10560745	46	Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.	Smithkline Beecham Pharmaceuticals
10522712	109	The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.	British Biotech Pharmaceuticals
10411481	144	Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.	Cea
10406637	20	Synthesis and identification of conformationally constrained selective MMP inhibitors.	Searle Discovery Research
10360755	17	P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.	Dupont Pharmaceuticals
10230616	30	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.	Searle Discovery Research
10229623	82	Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.	Pharmacia and Upjohn
10212120	34	Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.	Affymax Research Institute
10052961	24	Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.	RhôNe-Poulenc Rorer
10021927	80	Design and synthesis of thiol containing inhibitors of matrix metalloproteinases.	Novartis Biomedical Research Institute
10021913	42	Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.	Pfizer
9873712	109	Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.	Abbott Laboratories
9873491	56	The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.	Abbott Laboratories
9873489	28	Design and synthesis of conformationally-constrained MMP inhibitors.	Procter and Gamble Pharmaceuticals
9873367	39	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.	Abbott Laboratories
9871728	27	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
9871727	58	Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.	Affymax Research Institute
9871623	48	Selective inhibition of low affinity IgE receptor (CD23) processing.	Smithkline Beecham Pharmaceuticals
9871622	36	Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing.	Smithkline Beecham Pharmaceuticals
9871551	48	Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.	Dupont Pharmaceuticals
9632351	36	Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.	Affymax Research Institute
9599226	25	Macrocyclic amino carboxylates as selective MMP-8 inhibitors.	Dupont Pharmaceuticals
9599225	9	Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.	Dupont Pharmaceuticals
9548812	67	Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.	Kanebo
9484512	130	Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.	Shionogi
9191969	31	Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.	Institut De Recherche Servier
8289190	31	Synthesis of novel N-phosphonoalkyl dipeptide inhibitors of human collagenase.	Smithkline Beecham Pharmaceuticals
8277511	57	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.	Merck Research Laboratories
8258825	31	Synthesis of novel modified dipeptide inhibitors of human collagenase: beta-mercapto carboxylic acid derivatives.	Smithkline Beecham Pharmaceuticals
8126708	113	Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.	Glaxo Inc. Research Institute
7629797	73	Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.	Sterling Winthrop Pharmaceuticals Research Division
22299577	12	Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.	Universit?? Di Firenze
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
9463476	21	DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.	Suntory Institute For Bioorganic Research
8632342	110	Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.	Eli Lilly
7680751	48	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.	National Institute of Neurological Disorders and Stroke
19695884	156	Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.	Vernalis (R&D)
17034127	45	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.	University of Newcastle Upon Tyne
19345579	14	Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.	Wyeth Research
19267461	53	Novel tricyclic inhibitors of IkappaB kinase.	Bristol-Myers Squibb